Table 1 Patient clinical characteristics

From: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study

 

Study sample as a whole

Patient subsets

All

Non-remitters

Remitters

C1A

C1B

C2A

C2B

Number of patients

325

102

223

97

62

95

71

Male (%)

70.2%

73.5%

68.6%

63.9%

83.9%

63.4%

75.3%

Age (years)

26.2 ± 6.2

25.0 ± 5.6

28.8 ± 6.4

25.9 ± 5.9

25.6 ± 5.6

27.0 ± 7.0

26.2 ± 6.0

BMI (kg/m2)

23.3 ± 4.2

23.5 ± 4.5

23.2 ± 4.1

23.3 ± 4.0

23.8 ± 3.8

23.2 ± 4.5

23.0 ± 4.5

Waist circumference (cm)

83.2 ± 11.8

84.6 ± 11.6

82.6 ± 11.9

83.2 ± 11.8

85.2 ± 11.6

82.3 ± 12.2

82.8 ± 10.3

PPANSS

19.8 ± 5.7

21.4 ± 5.4

19.1 ± 7.7

24.6 ± 4.1

17.2 ± 4.3

21.3 ± 4.1

14.0 ± 3.3

NPANSS

19.6 ± 7.1

22.5 ± 7.2

18.3 ± 6.7

25.7 ± 5.0

24.9 ± 3.9

14.5 ± 4.0

13.5 ± 4.0

GPANSS

38.2 ± 9.8

40.6 ± 8.8

37.0 ± 10.0

47.8 ± 6.8

37.5 ± 7.0

36.9 ± 6.3

27.6 ± 5.9

PANSS total

77.6 ± 19.0

84.5 ± 16.7

74.4 ± 19.6

98.1 ± 12.6

79.7 ± 9.8

72.6 ± 9.8

55.0 ± 9.6

CDSS

13.2 ± 4.8

13.2 ± 5.0

13.2 ± 4.7

14.1 ± 5.5

13.0 ± 4.8

13.7 ± 4.7

11.6 ± 3.3

PSP

48.9 ± 15.2

45.5 ± 15.6

50.5 ± 14.8

45.0 ± 13.2

44.9 ± 15.3

47.6 ± 14.1

59.2 ± 14.4

Recreational drug use

48.9%

48.0%

49.3%

39.2%

38.7%

53.8%

64.4%

Seropositivity to T. gondii

23.7%

30.2%

20.8%

30.9%

23.7%

17.4%

22.4%

Seropositivity to CMV

56.1%

56.3%

56.0%

60.6%

45.8%

60.9%

52.2%

Seropositivity to HSV-1

58.0%

56.3%

58.8%

63.8%

44.1%

64.1%

53.7%

Remitters

68.60%

0.00%

100.00%

57.70%

54.80%

61.30%

90.40%

  1. The total number of patients, proportion of males, age (mean ± SEM), BMI (mean ± SEM), waist circumference (mean ± SEM) and clinical scores (mean ± SEM) before treatment are indicated in the study sample as a whole (all patients, non-remitters and remitters), and in the indicated subtypes. The proportion (%) of patients reporting recreational drug use, test seropositive for the indicated pathogens, or identified as remitters after 4 weeks of treatment with amisulpride are also indicated
  2. BMI bone marrow index, PANSS Positive and Negative Syndrome Scale, PPANSS positive PANSS, NPANSS negative PANSS, GPANSS general psychopathology PANSS, CDSS Calgary Depression Scale for Schizophrenia, PSP Personal and Social Performance Scale, CMV cytomegalovirus, HSV-1 herpes simplex virus type 1
Back to article page